TED
04.02.21
Horizon Therapeutics to Resupply Market With Tepezza for the Treatment of Thyroid Eye Disease (TED) Beginning in AprilSource: Horizon Therapeutics
02.24.21
New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic PhaseSource: Horizon Therapeutics
02.03.21
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 for Thyroid Eye DiseaseSource: Immunovant
11.16.20
Horizon: New Data Build on Growing Evidence Supporting Tepezza Efficacy in Thyroid Eye Disease (TED)Source: Horizon Therapeutics
11.11.20
New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO VirtualSource: Horizon Therapeutics
10.14.20
Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.31.20
New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.01.20
New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye HealthSource: Horizon Therapeutics
05.14.20
New Data on the Pharmacokinetic Profile of Tepezza Reinforce the Labeled Dosing RegimenSource: Horizon Therapeutics
05.11.20
US Physician Survey Illustrates the Impact of Thyroid Eye Disease on Patient Quality of LifeSource: Horizon Therapeutics